Since CRISPR-Cas ko for EZH2 in HC116 cells was not successful (data not shown) in an attempt to mimic EZH2 status of CRC tumors at the invasion front, we treated HCT116 colon tumor cells with a common EZH2 inhibitor (DZNep) that is known to decrease the activity and protein level of EZH2 (Tan et al. 2007; Sun et al. 2009). This evidence concerns the gene EZH2 and colorectal carcinoma.